Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32681842 | 0.83 | DPP7 (0.35) | USP30DPP7 | |
| SCHEMBL20744928 | 0.83 | DPP7 (0.35) | USP30DPP7 | |
| SCHEMBL3572947 | 0.81 | USP30 (0.33) | TEAD1EPHX1RBP4KDM1AEPHX2 | |
| SCHEMBL3580062 | 0.81 | USP30 (0.33) | TEAD1EPHX1RBP4KDM1AEPHX2 | |
| SCHEMBL10592500 | 0.76 | DPP7 (0.46) | DPP7 | |
| SCHEMBL10592508 | 0.76 | DPP7 (0.46) | DPP7 | |
| SCHEMBL30208797 | 0.75 | SMN1; SMN2 (0.53) | USP30 | |
| SCHEMBL30208781 | 0.75 | SMN1; SMN2 (0.53) | USP30 | |
| SCHEMBL22555215 | 0.75 | ESR1 (0.30) | — | |
| SCHEMBL22554963 | 0.75 | ESR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3318565-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3318565-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | Pfizer Inc (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3077395-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9617258-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3077395-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | Pfizer Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. | 2015-06-11 | — | — | US | disclosed |
| WO-2015083028-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | TEAD1 4674/4885EPHX1 2642/4885RBP4 4365/4885 |
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | TEAD1 4809/4885EPHX1 2436/4885RBP4 3230/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | TEAD1 4842/4885EPHX1 3580/4885RBP4 3591/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | TEAD1 4674/4885EPHX1 2642/4885RBP4 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.